ReviewSmart molecules : open access2025
Acute kidney injury and iron metabolism: A narrative review focusing on pathophysiology and therapy.
Review in Smart molecules : open access, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Iron Paradox in Acute Kidney Injury.Kidney360 · 2026Article
- Iron Biology in Acute Kidney Injury: Catalytic Iron, Hepcidin-Ferroportin Axis, and NGAL-A Narrative Review.International journal of molecular sciences · 2026Review
- Acute kidney injury and iron metabolism: A narrative review focusing on pathophysiology and therapy.Smart molecules : open access · 2025Review
- Clinical Outcomes of Iron Supplement Therapy in Non-Anemic Female CKD Stage 3 Patients with Low Serum Ferritin Level: A Multi-Institutional TriNetX Analysis.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) represents a substantial challenge to public health and is characterized by elevated occurrence and fatality rates. In the last 3 decades, the disruption of iron homeostasis and the cytotoxic effects mediated by iron have been extensively acknowledged as contributors to, as well as outcomes of, renal damage. Therefore, iron metabolism has become the focus of novel therapeutic interventions for AKI, with targeted iron metabolism strategies showing great potential. In this review, we have explored the dysregulation of iron metabolism in AKI and the AKI caused by iron metabolism disorders. We have summarized the complex mechanisms of iron metabolism in the kidney and emphasized the potential role of iron metabolism-related metabolic pathways in the treatment and prevention of AKI. Finally, we have reviewed various strategies targeting iron metabolism for the treatment of AKI, hoping to provide more effective treatment options for AKI patients in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.